Table 1. Characteristics of the 11 studies included in the analysis.
| Study | Location | Year | Sample size (n) |
Spherical equivalent (D) |
Age (y) |
Type of OCT | Quality score | |||
| Myopia | Non-myopia | Myopia | Non-myopia | Myopia | Non-myopia | |||||
| Li[33] | China | 2016 | 65 | 71 | -1.50±1.0 | 0±0.5 | 11.4±1.5 | 11.5±1.7 | Cirrus-HD OCT | 8b |
| Bulut[26] | Turkey | 2016 | 53 | 64 | -2.1±1.0 | 0.0±0.3 | 10.9±3.4 | 11.7±2.7 | Cirrus HD | 8b |
| Jin[34] | China | 2016 | 86 | 91 | -2.00±1.45 | 0.18±0.26 | 10.1±1.1 | 10.1±1.1 | SS-OCT Topcon DRI OCT-1 | 9b |
| Lundberg[36] | Denmark | 2018 | 55 | 252 | -1.77±1.6 | 0.75±0.6 | 15.4±0.6 | 15.4±0.7 | Spectralis OCT | 9b |
| Lee[37] | Korea | 2017 | 28 | 39 | -2.83±1.17 | 0.08±0.50 | 8.4±1.7 | 8.1±1.8 | Spectralis OCT | 9b |
| Deng[38] | China | 2019 | 222 | 49 | -2.96±1.67 | 0.05±0.24 | 12.37±1.80 | 11.45±1.53 | SS-OCT Topcon DRI OCT-1 | 8b |
| Guo[39] | China | 2019 | 1020 | 410 | -2.88±2.63 | -0.25± 0.63 | 13.0±1.0 | 13.0±1.0 | Spectralis OCT | 9b |
| Read[41] | Australia | 2013 | 41 | 60 | -2.39±1.51 | +0.33±0.31 | 13±1.5 | 13.1±1.2 | Spectralis OCT | 9b |
| Jiang[42] | China | 2021 | 43 | 28 | - | - | 6.51±0.51 | 6.43±0.50 | Optovue SD-OCT | 7a |
| Matalia[43] | India | 2017 | 40 | 46 | - | - | - | - | Optovue SD-OCT | 8b |
| Chang[44] | China | 2022 | 40 | 19 | -2.21±1.26 | 0.35±0.46 | 8.55±1.63 | 8.18±2.44 | VG200S; SVision Imaging | 10b |
aThe Newcastle Ottawa Scale was used for quality assessment in the included studies; bThe Agency for Healthcare Research and Quality was used for quality assessment in the included studies. OCT: Optical coherence tomography.